Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID05977998

A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology

Led by M.D. Anderson Cancer Center · Updated on 2026-05-22

30

Participants Needed

1

Research Sites

104 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are studying the effects of paclitaxel combined with gastrectomy (surgery to remove all or part of the stomach) on patients diagnosed with stage IV gastric or gastroesophageal cancer who have positive cytology or carcinomatosis. The main goal is to assess overall survival from diagnosis and to evaluate the safety of gastrectomy after perioperative intraperitoneal paclitaxel treatment. This is a Phase II clinical trial sponsored by M.D. Anderson Cancer Center. Participants receive paclitaxel by intraperitoneal injection every two weeks for six weeks. Depending on the doctor's recommendation, participants may then undergo gastrectomy surgery. After surgery, additional paclitaxel treatment is given every two weeks for another six weeks. Other supportive medications such as dexamethasone, diphenhydramine, and famotidine are also administered intravenously as part of the treatment regimen. During the study, participants will be monitored for adverse events using standard criteria throughout the average one-year follow-up period. Assessments will include evaluations of overall survival and treatment safety. The study involves regular visits for treatment administration, safety monitoring, and follow-up evaluations. Participation duration varies but involves perioperative treatment and monitoring over approximately one year.

CONDITIONS

Brief Title

A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older with no upper age limit
  • ECOG performance status of 2 or less (Karnofsky 60% or higher)
  • Cytologic or histologic confirmation of adenocarcinoma of the stomach or gastroesophageal junction
  • Adequate kidney and bone marrow function: leukocytes ≥ 3,000/uL, absolute neutrophil count ≥ 1,500/uL, platelets ≥ 60,000/μL, serum creatinine ≤ 1.6 mg/dL
  • Distant metastatic disease involving the peritoneum with positive cytology or carcinomatosis confirmed by laparoscopy or laparotomy
  • Completion of preoperative systemic cytotoxic chemotherapy; targeted or immunotherapy may continue
  • Open to English and non-English speaking patients
Not Eligible

You will not qualify if you...

  • Metastatic disease beyond the peritoneum such as to liver, brain, or lungs
  • Active infections like pneumonia or wound infections that prevent treatment
  • Positive pregnancy test or unwillingness to use adequate contraception or abstain from breastfeeding
  • Unstable angina or congestive heart failure Grade II or higher
  • Cognitive impairment or inability to comply with study procedures
  • Known life-threatening hypersensitivity to systemic chemotherapy used in this protocol
  • Previous surgery preventing safe tumor removal or intraperitoneal port placement

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Treatment

Duration - Approximately 12 weeks

Participants receive paclitaxel every 2 weeks for 6 weeks before possibly undergoing gastrectomy, followed by additional paclitaxel every 2 weeks for 6 weeks.

6 visits every 2 weeks before surgery and 6 visits every 2 weeks after surgery

Trial Site Locations

Total: 1 location

1

M D Anderson Cancer Center

Houston, Texas, United States, 77030

Actively Recruiting

Loading map...

Research Team

I

Iqra Rehman, RN

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Similar Trials

A Phase 1 Study to Evaluate the Safety and Efficacy of DISP-...

Colorectal Cancer

Actively Recruiting

3 locations

NeoTISLEGA - Phase Ib Trial of Tislelizumab Plus FLOT Chemot...

Esophagogastric Junction Adenocarcinoma

Actively Recruiting

4 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here